Shots and Shingles: What Do They Tell Us?

Lymphocytes, the lifelong sentinels of the immune system, are responsible for keeping latent infections and tumors under control. Herpes viruses lead the list of latent infections in humans worldwide. They include common herpesviruses (HSV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV).

Shingles result from reactivation of dormant VZV and betray a slackening of immune control over the virus. There are numerous reports of shingles occurring shortly after COVID vaccination. How and why this should occur after COVID 19-“vaccination” is yet unknown, but a number of possibilities come to mind.

  1. Once the “vaccines” reach the draining lymph nodes, their toxic lipid components can directly damage immune cells.
  2. Immune cells that produce the viral spike protein come under attack by reactive killer lymphocytes.
  3. Individuals receiving the second injection will have produced antibodies against the spike protein. Immunological attack on spike protein-producing cells will be multiplied and magnified through the action of these antibodies and complement.

These events lead to swelling and tenderness of axillary lymph nodes as observed especially after second injections.

Death of dendritic cells and lymphocytes lead to slackening of immunological control that we anticipate extends to tumor surveillance and to dormant infections other than VZV. Prominent amongst the latter are EBV, CMV and also toxoplasmosis and tuberculosis. Our physician colleagues are urged to consult medical textbooks for reviews on the possible clinical consequences. We should be reminded that complications of infectious mononucleosis – the disease caused by an initial infection with EBV – occur infrequently; but if they do, they may be so dramatic as to be the predominant manifestation of the illness. These complications include thrombocytopenia, encephalitis, Bell’s palsy and other cranial nerve palsies, Guillain-Barre syndrome, seizures, transverse myelitis, psychosis, myocarditis and interstitial pneumonitis. All of these have been reported as adverse events in persons who had received COVID vaccines. Thus, EBV reactivation must be considered whenever any of these symptoms occur after vaccination.

We also draw attention to warnings by clinical pathologist Dr. Ryan Cole, who reports that in his own diagnostic lab there has been a very significant increase in the number of histopathological cancer diagnoses since the “vaccinations” started. Cole attributes this to the immunosuppressive effect of the “vaccines.” We end with a note to the general audience that reactivation of CMV and toxoplasmosis infections during pregnancy possibly raises the danger of congenital infection and irreparable harm to the child.

For additional information on vaccine-immune interactions see also Leaky Blood Vessels: An Unknown Danger of Vaccination, and Letter to Physicians: Four New Scientific Discoveries Regarding COVID-19 Immunity and Vaccines